Elysium Health
Elysium Health is a company.
Active
Updated: ·
Financial History
Total Raised
N/A
Valuation
N/A
Leadership Team
Key people at Elysium Health.
Elysium Health is a company.
Key people at Elysium Health.
Key people at Elysium Health.
Elysium Health is a consumer health company dedicated to translating scientific advancements in aging research into accessible products and technologies.[1][2][3] It develops clinically validated supplements like Basis (which replenishes NAD+ to combat cellular aging and boost energy) and Matter (a micronutrient complex for brain aging, developed with Oxford based on the VITACOG study), targeting individuals seeking proactive health solutions for longevity and wellness.[4] The company serves everyday consumers through direct-to-consumer sales, addressing multi-factor aging problems like cellular decline and cognitive health with a science-first approach backed by partnerships with MIT, Oxford, Yale, and a Scientific Advisory Board including eight Nobel laureates.[1][4] Growth is evidenced by a $40 million Series C funding round in prior years to expand its product pipeline, customer base, and clinical trials.[7]
Elysium Health emerged from pioneering aging research starting in 1982, when co-founder and chief scientist Dr. Leonard Guarente, fresh from his Harvard Ph.D., established a lab at MIT to study genetic and molecular causes of aging using baker's yeast (Saccharomyces cerevisiae).[2] Guarente's breakthroughs on sirtuins and NAD+—key molecules in cellular health—laid the groundwork for products like Basis.[1][2] In recent years, he partnered with CEO Eric Marcotulli (from tech and VC backgrounds) and co-founder Dan Alminana to commercialize this science, founding Elysium to make research directly accessible to consumers amid accelerating discoveries like the hallmarks of aging and potential reversal mechanisms.[1][2][4] Early traction came from rigorous clinical validation and institutional ties, humanizing the mission to democratize longevity science.[1][7]
Elysium rides the geroscience wave, capitalizing on 20+ years of breakthroughs like sirtuins, NAD+, hallmarks of aging, and early reversal evidence to pioneer proactive, consumer-facing longevity solutions.[1][2] Timing aligns with booming direct-to-consumer health trends, where aging research shifts healthcare from reactive treatment to prevention, fueled by genomic mapping and cellular metabolism insights.[1][2] Market forces like rising demand for science-backed wellness (amid press acclaim and clinical trial momentum) favor Elysium, influencing the ecosystem by setting standards for rigor—collaborating with academia to bridge labs and consumers, potentially redefining health as a daily, accessible practice.[4][7]
Elysium is poised to expand its pipeline with new tests, interventions, and trials, leveraging funding for broader reach in the exploding longevity market.[7] Trends like AI-driven personalized aging tech and regulatory nods for NAD+ therapies will accelerate growth, evolving its influence from niche supplements to ecosystem leader in evidence-based healthspan extension. This builds on its core mission, turning yesterday's yeast lab discoveries into tomorrow's everyday vitality.[1][2]
